December 6, 2013
FOR IMMEDIATE RELEASE
Contact: Bruce Janele, 800-457-4777
TIMONIUM, Maryland, December 6, 2013 - CurePSP and Karin & Sten Mortstedt CBD Solutions, a Swedish organization focused on curing corticobasal degeneration (CBD), have entered into a partnership to develop a unified clinical rating scale for CBD, a measurement and diagnosis tool for use by neurologists. Clinical rating scales are critical in determining both disease progression and the results of studies and clinical trials. Currently, no clinical rating scale exists for CBD.
Stockholm-based CBD Solutions will provide a $292,000 grant through CurePSP to internationally recognized movement disorder experts Irene Litvan, MD, Director of the Movement Disorder Center at the UC San Diego Neurological Institute, and Lawrence Golbe, MD, Director of the Movement Disorders Division at Rutgers Robert Wood Johnson Medical School, who will serve as co-principal investigators for the project. Dr. Golbe helped create the first clinical rating scale for progressive supranuclear palsy (PSP), which is now used by neurologists worldwide.
"At a time when the prospects of having therapeutic agents that could potentially slow or stop the disease progression of tauopathies is imminent, it is important to make sure that we have a validated rating scale that all investigators can use, which can also serve as a way to track the response to medications," said Dr. Irene Litvan. "This grant will allow us to develop such a scale and to validate it in 100 patients with CBD."
Once complete, the CBD rating scale will be used to determine the state and rate of disease progression in patients, measure the effectiveness of new treatments intended to slow the progression of the disease, and evaluate the benefit of medications. The 20 month project will involve the participation of CBD patients at up to 20 different sites across the United States, Scandinavia and Europe. Patient recruitment for the project is expected to begin in June of 2014.
“CurePSP’s new relationship with CBD Solutions opens a new and important chapter in understanding corticobasal degeneration and related tauopathies,” said Richard Gordon Zyne, DMin, President-CEO of CurePSP. “The development of a clinical rating scale for CBD is an essential element in helping those who are currently suffering with the disorder and for the future development of possible treatments and therapies. We are truly grateful to be part of this important international effort.”
CurePSP is the foremost non-profit organization dedicated to increasing awareness of progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and other atypical Parkinsonian disorders; funding research toward treatment, cure and prevention; educating healthcare professionals; and providing support, information and hope for affected persons and their families.